<SEC-DOCUMENT>0001070081-20-000017.txt : 20200113
<SEC-HEADER>0001070081-20-000017.hdr.sgml : 20200113
<ACCEPTANCE-DATETIME>20200113082002
ACCESSION NUMBER:		0001070081-20-000017
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200113
DATE AS OF CHANGE:		20200113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		20522889

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k11320.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:061c4cc645b34d0c81b93f6fa44d1566,x:225ee35ebf034766a552fd2399a36229-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ptct="http://www.ptcbio.com/20200113" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q1" name="dei:AmendmentFlag" id="Fact-49894D4EBC5C5317941BF8FDE3D756B4-wk-Fact-49894D4EBC5C5317941BF8FDE3D756B4" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q1" name="dei:EntityCentralIndexKey" id="Fact-6E26546466E6574883EB744C37EEF147-wk-Fact-6E26546466E6574883EB744C37EEF147">0001070081</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20200113.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-13</xbrli:startDate>
			<xbrli:endDate>2020-01-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="sDFF34286FCCB506BB04FE3934A82056E"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d95908408e68-wk-Fact-E2C4E76C41225B26B5DEA722FCC963D6" name="dei:DocumentType" contextRef="D2020Q1"><span style="font-size:18pt;font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d95908408e82-wk-Fact-CDE8F1F120D0543FAFCEEAAC9021ABC4" name="dei:DocumentPeriodEndDate" contextRef="D2020Q1" format="ixt:datemonthdayyearen">January 13, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d95908408e87-wk-Fact-9A35845C1A205519937E58166F074120" name="dei:EntityRegistrantName" contextRef="D2020Q1"><span style="font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e111-wk-Fact-3CDD51E03C405C9B909036B4C8A12EA9" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q1" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e121-wk-Fact-78F82EC654CF58FC86B3D998A0A0C7B8" name="dei:EntityFileNumber" contextRef="D2020Q1">001-35969</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e131-wk-Fact-152DD2716F975842A7CA0325C2C90DA0" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q1">04-3416587</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Commission</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">File Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(IRS Employer</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:141px;"></td><td style="width:114px;"></td><td style="width:33px;"></td><td style="width:228px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e183-wk-Fact-75D0788EB183565491B70CF2FCA5B2F2" name="dei:EntityAddressAddressLine1" contextRef="D2020Q1">100 Corporate Court</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e204-wk-Fact-1C0377C033945972A1B05CB05A4FAB5C" name="dei:EntityAddressCityOrTown" contextRef="D2020Q1">South Plainfield,</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e209-wk-Fact-47046F841EBD55A8BC7A456CFA67FAC3" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q1">NJ</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d95908408e219-wk-Fact-1135E67922FF5333A7F972230EF4558A" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q1">07080</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d95908408e246-wk-Fact-01D96A6606F855F5A98AD34F18C5ED0B" name="dei:CityAreaCode" contextRef="D2020Q1">(908)</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d95908408e250-wk-Fact-517A0F88B17453EB942D688EBF0283F2" name="dei:LocalPhoneNumber" contextRef="D2020Q1"><span style="font-weight:bold;">222-7000</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">see</span><span style="font-family:inherit;font-size:10pt;"> General Instruction A.2. below):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d95908408e271-wk-Fact-BD66DD45B22C5A3386A6D78653AD5442" name="dei:WrittenCommunications" contextRef="D2020Q1" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d95908408e281-wk-Fact-674F2A17301B508BAF172AB19694A02D" name="dei:SolicitingMaterial" contextRef="D2020Q1" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d95908408e291-wk-Fact-433E8FBE5DB15BFEBEFE17C918DB74BA" name="dei:PreCommencementTenderOffer" contextRef="D2020Q1" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d95908408e301-wk-Fact-16BA4E0C6C485926B2F0522C22B3BF5D" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q1" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d95908408e343-wk-Fact-14C1E52EF8805C6EAF64F769A1759FC0" name="dei:Security12bTitle" contextRef="D2020Q1">Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d95908408e348-wk-Fact-0BC389E12A955C409C3847509ACA70F8" name="dei:TradingSymbol" contextRef="D2020Q1">PTCT</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d95908408e353-wk-Fact-499DD750538556B099C8B81713503A75" name="dei:SecurityExchangeName" contextRef="D2020Q1" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d95908408e363-wk-Fact-00E4CB7DF6B451BC883D706A217FAC62" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q1" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;  </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s8F121F3034FD5CD2B7EF56E8F737DFBA"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02. &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">On January 13, 2020, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release (the &#8220;press release&#8221;) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2019, including that the Company expects to report (i) total unaudited revenue of approximately $306 million, including net product revenue for the Duchenne muscular dystrophy ("DMD") franchise of approximately $291 million and a $15 million milestone payment from F. Hoffmann La Roche Ltd and Hoffmann La Roche Inc. (collectively, "Roche") for the risdiplam New Drug Application acceptance; (ii) net product revenue for Translarna&#8482; of approximately $190 million, (iii) net product revenue for Emflaza</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">of approximately $101 million and (iv) ending cash and cash equivalents of approximately $686 million. Final results are subject to completion of the Company&#8217;s year-end audit.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also announced financial guidance for its fiscal year ending December 31, 2020 in the press release, including that the Company anticipates (i) full-year net product revenues for the DMD franchise to be between $320 and $340 million and (ii) GAAP R&amp;D and SG&amp;A expense for the full year 2020 to be between $610 and $640 million with non-GAAP R&amp;D and SG&amp;A expense for the full year 2020 to be between $545 and $575 million, excluding estimated non-cash, stock-based compensation expense of approximately $65 million.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company announced that on Wednesday, January 15th at 8:30 am PT at the 38th Annual J.P. Morgan Healthcare Conference, the Company will present its 2020 strategic priorities, preliminary 2019 financial results, and 2020 financial guidance. The presentation will be webcast live on the Events and Presentations page under the Investors section of the Company&#8217;s website. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Current Report on Form 8-K and Exhibit 99.1 include a forward-looking financial measure that was not prepared in accordance with accounting principles generally accepted in the United States (GAAP), non-GAAP R&amp;D and SGA expenses (which excludes non-cash stock-based compensation expense). Management uses this measure when assessing and identifying operational trends and, in management&#8217;s opinion, this non-GAAP measure is useful to investors and other users of its financial statements by providing greater transparency into the historical and projected operating performance of PTC and the Company&#8217;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward Looking Statements</span><span style="font-family:inherit;font-size:10pt;">:&#160;All statements, other than those of historical fact, contained in this Current Report on Form 8-K, are forward-looking statements, including preliminary (unaudited) financial information for fiscal year 2019 and financial guidance for fiscal year 2020. The Company's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to the preliminary nature of the Company's 2019 financial information, which is subject to completion of the Company's year-end audit; the assumptions underlying the Company's financial guidance for 2020; and the factors discussed in the &#8220;Risk Factors&#8221; section of the Company's Annual Report on Form 10-K for the year ended December 31, 2018, Quarterly Reports on Form 10-Q for the periods ended March 31, 2019, June 30, 2019 and September 30, 2019 as well as any updates to these risk factors filed from time to time in the Company's other filings with the Securities and Exchange Commission. You are urged to carefully consider all such factors. The forward-looking statements contained herein and the exhibit hereto represent the Company's views only as of the date of this Current Report on Form 8-K and the Company does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this Current Report on Form 8-K except as required by law. All website addresses given in this Current Report on Form 8-K or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(d) Exhibits</span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit991pressrelease.htm"><span style="font-family:inherit;font-size:10pt;">Press Release, dated January 13, 2020 issued by PTC Therapeutics, Inc.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: January 13, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991pressrelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s335B6D492626BA378D619ED6A8F5C795"></a></div><div></div><div><br></div><div style="line-height:138%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:138%;text-align:left;"><img src="exhibit991pressreleas_image1.gif" alt="exhibit991pressreleas_image1.gif" style="height:94px;width:156px;"></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">- 3 clinical trials from PTC&#8217;s new redox platform to begin in 2020 -</font></div><div style="line-height:138%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">- ~ $306 million preliminary unaudited 2019 total revenue</font><font style="font-family:Arial;font-size:12pt;">&#32;&#8211;</font></div><div style="line-height:138%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">- 2020 Duchenne franchise revenue guidance of $320-340 million -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SOUTH PLAINFIELD, N.J. January 13, 2020 </font><font style="font-family:Arial;font-size:12pt;">&#8211;&#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today is providing a corporate update that will be presented at the 38</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;Annual J.P. Morgan Healthcare Conference on Wednesday, January 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;at 8:30 a.m. PST. Stuart W. Peltz, Ph.D., PTC&#8217;s Chief Executive Officer, will provide an update on the 2019 accomplishments and highlight value creating events in the upcoming year. Additionally, the Company is providing preliminary 2019 financial results and 2020 financial guidance. The presentation will be webcast live on the Events and Presentations page under the investors&#8217; section of PTC Therapeutics&#8217; website at </font><font style="font-family:Arial;font-size:12pt;color:#006ebf;">www.ptcbio.com</font><font style="font-family:Arial;font-size:12pt;">&#32;</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Corporate Highlights:</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Gene Therapy Platform Update:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC has submitted a Marketing Authorization Application (MAA) for the potential approval of a gene therapy treatment, PTC-AADC, for AADC deficiency with the European Medicines Agency (EMA). PTC expects the Committee for Medicinal Products for Human Use (CHMP) opinion in 2H 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">In a recent interaction with the U.S. Food and Drug Administration (FDA) there was a request for additional information concerning the use of the commercial delivery system for PTC-AADC in young patients</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:Arial;font-size:12pt;">Patients have been identified who are immediately available for treatment with the commercial delivery system. We anticipate that this will cause a short delay of the Biologics License Application (BLA) and should allow for submission to the FDA in 2Q 2020. </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:17px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC has identified 200 AADC patients to date and continues to anticipate that over 300 AADC patients will be identified by launch. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC-FA gene therapy for Friedreich ataxia is progressing and is anticipated to enter the clinic in 3Q 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In order to control and accelerate its gene therapy platform, PTC secured a 15-year lease on ~185,000 sq. ft. of space, which includes a state-of-the-art biologics production facility with supporting research and operations buildings in NJ. PTC expects manufacturing to begin at this facility in 2020.</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Risdiplam Regulatory &amp; Clinical Updates:&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The risdiplam Prescription Drug User Fee Act (PDUFA) date for a decision by the FDA is May 24, 2020. Risdiplam is expected to be indicated for spinal muscular atrophy (SMA) type 1, 2 &amp; 3 patients, if approved.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In November 2019, PTC announced that the pivotal part of the SUNFISH trial in SMA type 2/3 patients was successful, meeting its primary endpoint. Data from the pivotal part of SUNFISH will be presented at the SMA Europe Conference from February 5 &#8211; 7, 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Topline results from the pivotal portion of the open label FIREFISH study in type 1 SMA patients are anticipated in 1Q 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The SMA program has studied the broadest cohort of SMA patients in clinical trials to date. This program is a collaboration between PTC, Roche and the SMA Foundation. </font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Expanding commercial platform:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Duchenne muscular dystrophy (DMD) franchise, consisting of Translarna&#8482; and Emflaza</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:12pt;">, continues to grow with 2019 unaudited revenue of approximately $291 million. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Translarna&#8482; continues to grow with further penetration into existing territories, geographic expansion into new territories, increased awareness and earlier diagnosis. PTC plans to re-submit the Translarna New Drug Application (NDA) to the FDA with the data from the dystrophin study in mid-year 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Growth in Emflaza</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;revenue was based on a recent label expansion in the 2-5-year-old patient population, and reduced payer restrictions resulting from multiple publications showing benefit of Emflaza relative to prednisone. One such recent </font><font style="font-family:Arial;font-size:12pt;color:#006ebf;">publication</font><font style="font-family:Arial;font-size:12pt;">, which included real-world data from Cincinnati Children&#8217;s hospital, specifically highlighted the benefit of switching from prednisone to Emflaza. </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Tegsedi</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;(inotersen) received approval from the Brazilian health regulatory authority (ANVISA) for the treatment of stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR), to delay disease progression and improve quality of life. The commercial launch for Tegsedi is ongoing with patient and physician services to support the launch, including medical education and diagnosis efforts. </font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Growing pipeline and R&amp;D capabilities:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In 2020, PTC plans to initiate three trials in its newly acquired redox platform with two unique compounds that regulate inflammation and oxidative stress.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">These include potential registrational trials in mitochondrial epilepsy and Friedreich ataxia with PTC743. Additionally, a Phase 1 trial with PTC857 is also planned targeting GBA Parkinson&#8217;s disease. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In late 2020, PTC expects to file an investigational new drug (IND) application for its development candidate in Huntington disease. PTC has several additional programs from the splicing platform in development with undisclosed targets.</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Preliminary Unaudited 2019 Financial Results</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Total unaudited revenue for 2019 was approximately $306 million. This includes expected net product revenue for the Duchenne muscular dystrophy franchise of approximately $291 million for the full year 2019 and a $15 million milestone payment from Roche for the risdiplam NDA acceptance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC expects to report net product revenue for Translarna of approximately $190 million for full year 2019. As a reminder, the ANVISA approval in Brazil should lead to expanded market access in 2020 and beyond but led to a price discount that impacted 2019 net sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Additionally, PTC expects to report net product revenue for Emflaza of approximately $101 million for the full year 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC expects to report 2019 year-end cash and cash equivalents of approximately $686 million.</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC is currently in the process of finalizing its financial results for the 2019 fiscal year. The above information is based on preliminary unaudited information and management estimates for the full year 2019, subject to the completion of PTC's financial closing procedures. In addition, the above information is subject to revision as PTC completes its financial closing procedures for fiscal 2019.</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2020 Guidance</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#333333;">PTC anticipates full year net product revenues for the DMD franchise to be between </font><font style="font-family:Arial;font-size:12pt;">$320 </font><font style="font-family:Arial;font-size:12pt;color:#333333;">and $</font><font style="font-family:Arial;font-size:12pt;">340</font><font style="font-family:Arial;font-size:12pt;color:#333333;">&#32;million. New product launches, including Tegsedi, Waylivra, PTC-AADC and risdiplam, could contribute revenue in 2020. Remaining milestones and royalties from Roche on the SMA program are outlined in the table below. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#333333;">PTC anticipates GAAP R&amp;D and SG&amp;A expense for the full year 2020 to be between $610</font><font style="font-family:Arial;font-size:12pt;">&#32;</font><font style="font-family:Arial;font-size:12pt;color:#333333;">and $</font><font style="font-family:Arial;font-size:12pt;">640</font><font style="font-family:Arial;font-size:12pt;color:#333333;">&#32;million.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:156%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:156%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#333333;">PTC anticipates Non-GAAP R&amp;D and SG&amp;A expense for the full year 2020 to be between $</font><font style="font-family:Arial;font-size:12pt;">545 </font><font style="font-family:Arial;font-size:12pt;color:#333333;">and $</font><font style="font-family:Arial;font-size:12pt;">575</font><font style="font-family:Arial;font-size:12pt;color:#333333;">&#32;million, excluding estimated non-cash, stock-based compensation expense of approximately $65 million. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:156%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:156%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#333333;">The increase in R&amp;D and SG&amp;A expense are based in part on highly leverageable and scalable investments towards the $1.5 billion projected revenue in 2023, including gene therapy manufacturing, an increase in the number of programs advancing into the clinic and launches. </font></div></td></tr></table><div style="line-height:156%;padding-bottom:18px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#333333;font-weight:bold;">SMA Milestones/Royalties supporting information</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:15px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10.5pt;padding-left:-8px;"><font style="font-family:Arial;font-size:10.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#333333;">SMA program Milestone-based payments to PTC from Roche:</font></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.76851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Event</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Payment ($US)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;padding-left:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Filing of a MAA in an EU country or with the EMA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$15,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;padding-left:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Filing of an NDA in Japan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$ &#160; 7,500,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;padding-left:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">First Commercial Sale in US</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$20,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;padding-left:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">First Commercial Sale in the EU</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$20,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;padding-left:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">First Commercial Sale in Japan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$10,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Total Remaining</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$72,500,000</font></div></td></tr></table></div></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:15px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10.5pt;padding-left:-8px;"><font style="font-family:Arial;font-size:10.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#333333;">SMA program Royalties to PTC from Roche based on net sales:</font></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.76851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:68%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Tier of Calendar Year Worldwide Net Sales in $US million</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Percent (%) of Net Sales</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">0 &#8211; 500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; 500 &#8211; 1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">11</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; 1,000 &#8211; 2,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">14</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; 2,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">16</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:15px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10.5pt;padding-left:-8px;"><font style="font-family:Arial;font-size:10.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#333333;">SMA program Sales-threshold-based payments to PTC from Roche:</font></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.76851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:68%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:8px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Event</font></div><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Total Calendar Year Net Sales ($US) </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Payment ($US)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; $ 500,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$ &#160; 25,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; $ 750,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$ &#160; 50,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; $ 1,500,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$100,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&gt; $ 2,500,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$150,000,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Total Remaining</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$325,000,000</font></div></td></tr></table></div></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Non-GAAP Financial Measures:</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In this press release, the financial results and financial guidance of PTC are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, the non-GAAP financial measure excludes non-cash, stock-based compensation expense. This non-GAAP financial measure is provided as a complement to financial measures reported in GAAP because management uses this non-GAAP financial measure when assessing and identifying operational trends. In management's opinion, this non-GAAP financial measure is useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. A quantitative reconciliation of the non-GAAP financial measure to its closest equivalent GAAP financial measure is included in the table below.</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.37962962962963%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2020 R&amp;D and SG&amp;A Expense</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Low End of Range</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">High End of Range</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Projected GAAP R&amp;D and SG&amp;A Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">610,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">640,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Less: projected non-cash, stock-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">65,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">65,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">545,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">575,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">About PTC Therapeutics, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">For More Information:</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Investors:</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Alex Kane</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">+1 (908) 912-9643</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">akane@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Media:</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Jane Baj</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">+1 (908) 912-9167</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">jbaj@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Forward Looking Statements:</font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &#8220;2020 Guidance", including with respect to (i) 2020 net product revenue guidance and (ii) 2020 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and manufacturing capabilities; advancement of PTC's joint collaboration program in SMA, including any potential regulatory submissions, commercialization or royalty or milestone payments; PTC's expectations with respect to the licensing, regulatory submissions and potential commercialization of Tegsedi and Waylivra; expansion of commercialization of Translarna and Emflaza and related regulatory submissions; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. </font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#8217;s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC&#8217;s gene therapy platform, including any potential regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of studies under the SMA collaboration and events during, or as a result of, the studies that could delay or </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">prevent further development under the program, including any potential regulatory submissions and potential commercialization with regards to risdiplam; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi and Waylivra significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra, risdiplam or any of PTC's other product candidates; PTC's scientific approach and general development progress; PTC&#8217;s ability to satisfy its obligations under the terms of the lease agreement for its leased biologics facility; PTC's ability to satisfy its obligations under the terms of the senior secured term loan facility with MidCap Financial; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. </font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra or risdiplam.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:152%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptct-20200113.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20200113" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ptct="http://www.ptcbio.com/20200113" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200113_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200113_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200113_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200113_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPageDocument" roleURI="http://www.ptcbio.com/role/CoverPageDocument">
        <link:definition>0001000 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ptct_CoverpageAbstract" name="CoverpageAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>ptct-20200113_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200113.xsd#CoverPageDocument" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ptct-20200113_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200113.xsd#CoverPageDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ptct-20200113_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_label_en-US" xlink:label="lab_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_documentation_en-US" xlink:label="lab_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:loc xlink:href="ptct-20200113.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="lab_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_terseLabel_en-US" xlink:label="lab_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_label_en-US" xlink:label="lab_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:to="lab_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:to="lab_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_label_en-US" xlink:label="lab_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:to="lab_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:to="lab_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contained File Information, File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_label_en-US" xlink:label="lab_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:to="lab_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:to="lab_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:to="lab_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:to="lab_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:to="lab_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:to="lab_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_label_en-US" xlink:label="lab_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:to="lab_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:to="lab_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_label_en-US" xlink:label="lab_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:to="lab_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_label_en-US" xlink:label="lab_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:to="lab_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:to="lab_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_label_en-US" xlink:label="lab_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:to="lab_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_label_en-US" xlink:label="lab_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:to="lab_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_label_en-US" xlink:label="lab_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:to="lab_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:to="lab_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:to="lab_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_label_en-US" xlink:label="lab_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:to="lab_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ptct-20200113_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200113.xsd#CoverPageDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:href="ptct-20200113.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_DocumentType_66EAD1C4EB195C6CADA6BB0970FC71BD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_DocumentPeriodEndDate_2383BCE62EA15174BBF34B6AB0D736B2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityRegistrantName_CE0B0ECBCD715452B72B925F975B22E2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21CCA02DB84553BE97CEE861996560FF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityFileNumber_A84BD97BD81E5458A71113025508C292" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityTaxIdentificationNumber_E62DBE43A50057A9BAEAEF9C0CBFB49D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityAddressAddressLine1_42B155BDEF9354A495E92F851547EFA7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityAddressCityOrTown_CCF3B37D9F7C5413AC761CB6B14E47C2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityAddressStateOrProvince_BEA013F9B4215DD5AAB458FE4BC69301" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityAddressPostalZipCode_E1042F0FD96B57F690757FF18DF259BE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_CityAreaCode_16A88F459A245BEC98B75E6FEE242D22" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_LocalPhoneNumber_38054FFDF7DC5FC18D16FC829880BD35" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_WrittenCommunications_2FF0EA93A5135C80903856FAF2930B31" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_SolicitingMaterial_696E60CF6CF05FBC913BCE47009244BB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_PreCommencementTenderOffer_28EB9CF7117B52D8B5BCFCE333B1E782" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9472E64874365D0080AE2029B10DC034" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_Security12bTitle_E8285E05941057FFBEDFA6B181EBD9CF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_TradingSymbol_3F01EA8949D3593EAF85A3A204C27FEB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_SecurityExchangeName_DB24EA96CA7A58C792D17A9189282A78" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityEmergingGrowthCompany_D3D1D52AA5CF554C87F8ADB88C4E58E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_EntityCentralIndexKey_F1F9B78B715E51A9B7A237C12BC9D2B2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_D00257C9985F52398B517A0C65FE68DD" xlink:to="loc_dei_AmendmentFlag_E887B1693420506E9AEEF8866CBD6D48" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>exhibit991pressreleas_image1.gif
<DESCRIPTION>LOGO
<TEXT>
begin 644 exhibit991pressreleas_image1.gif
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MY2U5M))-\(B6P%2))FY&S&(:\YC()&:G> (&*M%+,FEI%L\$XK.M $UC8S'
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M"T=C.W"R,'&XZIYXJJV#L;"3(T<=E[<AT@UP6Q=RJZD9P0?743EZ"R(LAR)
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%[0$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W%7;>V+W]Q\87P;:!7W?1?@%02P,$%     @ @$(M4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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ME.PC-7[\CKL<LV>PW^;@%H=/,;RSF]=V];I)B^3JPDR([8B !P2[(Q(;^RX
MI  ,].R!#C0](^G90,\?Z)FW/XS(:8&<%,@1?>8)8,2<%IB1 C-$7W@"&+&D
M!>:DP!S15YX 1K"45EB0"@O,9YX$ 0GD>4E*+#'?3S0!"61Z14JL,-]/-0$)
MY)JEM)U2',%/-X4)))P%3,O^FW("PE8!$=JX#% $0+6!P 2J Z/]S;!] 7P5
M I,%5&B3,^QAR'T5 C,+J-!.9]C(,/=5",PBH$+;G6$WP])7(3 A%=KR#!L:
MT!TC,"$5VO4,>SI#=PQC@BJT\1FV=>;7+PH3*&! 6Q^PK3._A%&80 T#VOJ
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M)J$)<IQHNS"BL2P$$8WR1BUX:S2?-:PS%L/35B#E2SC"K\T5]]B0F/.Q#L=
M@HK5]*M>S'A<T0G\1[;(?:"]OXF66'$Q^&'PJ]&S_VTP",\.&C'._MAL]3T[
MMU9.[Z5HM8*XEM\63&XL6&1\K4,ZX\2KYPLWI?( .$HNX%!41^2[X_8,(ZZW
M:6QNU9S^AYK_]CZWH,%Q>13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U
M1'GAA<SIE_#PRJL^V?O4TR,O_0-^Q>_GUM#P0>)S6/$<S.EN?PHO3?*P99TW
MBISN]F>HQ:#>S@7WOT3Q U!+ P04    " " 0BU0V_W$-3T!   P @  #P
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M:W1-1X>LX'LQYT4,CQT>7S%1]_276<]>@C"MA[_)1/TUP.K795]02P,$%
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M4$L! A0#%     @ @$(M4'D[.L/O    *P(  !$              ( !F0$
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @$(M4)E<G",0!@  G"<
M !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " " 0BU0NC$RKZ,"  "7"P  &               @ 'X"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @$(M4$^XQO1D @  X 4
M !0              ( !T0L  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ @$(M4+JA.8K7 0  ,@8   T              ( !9PX  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " " 0BU0V_W$-3T!   P @  #P
M    @ %I$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ @$(M4/_ )@B]
M    A0(  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ @$(M4 N/V ,A 0  5P0  !,
M ( !R!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @  &A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>10
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "a8k11320.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "ptct-20200113_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptct-20200113_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "a8k11320.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20200113_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20200113_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20200113.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20200113",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k11320.htm",
      "contextRef": "D2020Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page Document",
     "role": "http://www.ptcbio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k11320.htm",
      "contextRef": "D2020Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Contained File Information, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "ptct_CoverpageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "cover page [Abstract]",
        "label": "cover page [Abstract]"
       }
      }
     },
     "localname": "CoverpageAbstract",
     "nsuri": "http://www.ptcbio.com/20200113",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="a8k11320.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="a8k11320.htm">a8k11320.htm</File>
    <File>exhibit991pressrelease.htm</File>
    <File>ptct-20200113.xsd</File>
    <File>ptct-20200113_cal.xml</File>
    <File>ptct-20200113_def.xml</File>
    <File>ptct-20200113_lab.xml</File>
    <File>ptct-20200113_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>a8k11320_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20200113.xsd" xlink:type="simple"/>
    <context id="D2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-01-13</startDate>
            <endDate>2020-01-13</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q1"
      id="Fact-49894D4EBC5C5317941BF8FDE3D756B4-wk-Fact-49894D4EBC5C5317941BF8FDE3D756B4">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q1"
      id="Fact-6E26546466E6574883EB744C37EEF147-wk-Fact-6E26546466E6574883EB744C37EEF147">0001070081</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q1"
      id="d95908408e68-wk-Fact-E2C4E76C41225B26B5DEA722FCC963D6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q1"
      id="d95908408e82-wk-Fact-CDE8F1F120D0543FAFCEEAAC9021ABC4">2020-01-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q1"
      id="d95908408e87-wk-Fact-9A35845C1A205519937E58166F074120">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q1"
      id="d95908408e111-wk-Fact-3CDD51E03C405C9B909036B4C8A12EA9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q1"
      id="d95908408e121-wk-Fact-78F82EC654CF58FC86B3D998A0A0C7B8">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q1"
      id="d95908408e131-wk-Fact-152DD2716F975842A7CA0325C2C90DA0">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q1"
      id="d95908408e183-wk-Fact-75D0788EB183565491B70CF2FCA5B2F2">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q1"
      id="d95908408e204-wk-Fact-1C0377C033945972A1B05CB05A4FAB5C">South Plainfield,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q1"
      id="d95908408e209-wk-Fact-47046F841EBD55A8BC7A456CFA67FAC3">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q1"
      id="d95908408e219-wk-Fact-1135E67922FF5333A7F972230EF4558A">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q1"
      id="d95908408e246-wk-Fact-01D96A6606F855F5A98AD34F18C5ED0B">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q1"
      id="d95908408e250-wk-Fact-517A0F88B17453EB942D688EBF0283F2">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q1"
      id="d95908408e271-wk-Fact-BD66DD45B22C5A3386A6D78653AD5442">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q1"
      id="d95908408e281-wk-Fact-674F2A17301B508BAF172AB19694A02D">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q1"
      id="d95908408e291-wk-Fact-433E8FBE5DB15BFEBEFE17C918DB74BA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q1"
      id="d95908408e301-wk-Fact-16BA4E0C6C485926B2F0522C22B3BF5D">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="D2020Q1"
      id="d95908408e343-wk-Fact-14C1E52EF8805C6EAF64F769A1759FC0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1"
      id="d95908408e348-wk-Fact-0BC389E12A955C409C3847509ACA70F8">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1"
      id="d95908408e353-wk-Fact-499DD750538556B099C8B81713503A75">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q1"
      id="d95908408e363-wk-Fact-00E4CB7DF6B451BC883D706A217FAC62">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6633459920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Jan. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CoverpageAbstract', window );"><strong>cover page [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 13,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Contained File Information, File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CoverpageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cover page [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CoverpageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001070081-20-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-20-000017-xbrl.zip
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M2%NCN2QV!HH0'&16A)2.M>U>EF1%2;40@V]8YD<8WQU!"YI'P1:J2/WZFBY
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MU8;T^),OI71BEV&ML$M1QXXUM"P%G*9I>N;0L8=CW?!4VS4G8V74QBX,5X;
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M3WEXT(6* QH-R$0A F</7Z$'$K3N4B^<X<_@(=I)*+.43MMN1SAM$S_$HSV
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MM7JCJX!<##+FB%N97!1HG0O_ V(__+]FA,7]Y,;/(UJR)USRJ/C W1U&P:Q
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M/$#5F6"_#0;2$TG#P,.@"&T)!QV@&V*$A"7W/!7&@=0CM.@U61PC9W&P,QZ
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M>8R"'3Z G.1LB&!*+9A25!JH4QJYI]6@-Y#/Y0M041*T^ 3D=SHRPCI+5"Q
M31T('WX$O<YZ0[IE?N^@M] B26R\,NWT"XU"T'OM4] 9\([]#&_"RQ\SP!P[
M!?-X?N?CP>$"4S'X1\JX.A])S[38C'DCH"T2Z&OLOWSL][GW;9@H4/E-JW@'
M] ^\Z%,$V$T$NC@ "G!SN&<-"PO,T]9QB^TKY9,AL9MDP"H^F#!2IXGEC_U=
MX ^$/M@AP%_XOK\R,"D(@CRWC.#]*&#-0YX"@R:)D//(G-+DL.%'T/^A2,CP
M\07:,V KZ8E.14CORR,7 .$)# F,*G@C6CK760TR@B[**6)>09S6'5]YP12Y
MK9RRXP%A!<9<7PA@5Q]ESD""S!J/%$-70 *5? F:*I@P?L9E0%Q*4LH)GV(2
M+Z=I"[P(F%G IXQSSRH%C]J8EA['F>%,@VQ,\5EPSNP\?9! K2&&\#Z#P1W!
M;16A^>$S@ (A X]F : G"-28^D?R5VN\*U7T*@!0*;!TO42:#DJ[CZ/$$1J-
MW&8?2/&MR0> ZTT>C/E$SUT5W7X;DJZS]GHE7:'E2RS3;;>-XG62 G&7AYA!
M$H$! /(*KU[D! 4C8DM3SSNWJ]1(?\("GD7>J%:HKU^A$LR:^[VJU8?";3\!
M,"1">B/PC?FYY#8 0"L6%,T"R$E= AK%V"G":$0U1;!1'"[=5!S6>'KY> ([
M3"44D5$DD1(5$%2X!_,HR(F7('@J>',K&.1D8-0F2\BIZ:PT,2K%<(V2HD'_
MZ:RO--H@Q?1?+39(6ZC"$1JB >8$0E5&7I#A(AQH^A3::JI!$UII8O2MG^OY
MV+@6J+@'@*M IM:!T5D<@WV \,9 $T\0_=!Y\&@2&W/J9S+ N:0 VI=?J_X,
M8"^#-Z990O:@6X]QEDC>F%V@:=W /KCQS$UC[-7%.8ZD]B6 )61'8I@!:!28
M?S_S,-YB.VZ]S$0]].;//W56VUO3_Z_#(:]-XF L.<F1@1%B+Y$Q<3=Y>:<:
MI-&^ +/>2]G\X>[I/ACT9#616P?.@"?)B ?+)S?B-3L #Z&[W+"JJX >_'1A
M45E&/GH+\)V\@IC"%V&F/8 H-  B,!Y-V/SQ 7J7DUBP#KS5XG8IM\4:3 YL
M*$;XUTJ&&K@O'[B@*K_ 9(=]P"<NHACUQZ,(?'@/T36RZX"Q/*/5\!C5F/5:
MCT^_['\Z_FCR U"A +P,NKJ+2R4#G^*$H'NU'F1!@X7"1 E1!\>)#'$!1T1^
MK&0$ZG073#V3:C"K6=?DI>N5V 43_RLO\-'[]D4_H86]%>;64=<:M5GX9K!^
MHF+*>7*K@],@0[O+K-7A9<!0!'YH7P1L_]/1'N%.IYE/MI,1H@2W'.@82BK[
M(G!;Y_>;65DUOEX!OJSX(0\5M#2MCP!>),E1P?J)XCZ&<CU%$4 49V7X %PN
MIES9V HN5CO7UZA_S.,( )O*QHW[(AUC<!.D=P.0X(U,/,9)Q'T,R=*=-PH(
MOMUES+WS&.B&VJD4YG6^8;V.^2IY-D^ R^UE?Z*=Q;Q[L+M09,8U,)Z@I2;[
M!?B7$N+AB8C#>)?7NUO$=7OA(.#?^=-D#X&+N;:\=:\,HD8UCCM,U-C$)BC-
MIDB2=&F"RCH-YV#+T1K*N^Y&Q^4)/C_;:JW[%'SDN/>RN;AB^>ME<-(4*UP"
MHD&68-"-@74EW+(G6/X*7%K+6*E(@!(JD0(\TJ% I1>/I(<^+^X_<?=C^G'E
M5AEA@IE&9V ,MEA$>>W CX(G@806?<F'D0+V-1$S$.L1]2T139/'0/JR& A!
MRZS2EE?COM 2;;':EJ\,^A77Q0D14.NYU1A*WX03GZ516#/&8S#&+X#\%,/"
M+UXOT$*\$_KHU?>)V50I[<&X2V5&-1FB31-&;X*5Y0Q><+=B#*#";0UBTT3X
M&<8<8CX!9@4O#8Q@ST2\C<N&LH'8*\0O,?!&G/4=7VI<'!_C+7W@_($D^]I2
M')['ALX$LFT,[412JPC,ZM\BW(_AC5SW'R3_LM2I.RO@RE("D@;F>JP2H%XA
M9';@9QE%T! F[@8^2+P\DW>D=(R)_@VF8^') 8(%%'.>D.M<DH)4&L08V#B.
MQ 65D&:6CG4V06UKW\-"$$,0%_)EB[]Y&2G K!;1 @D-$"I^D;V8*_\/"?\N
M \DC-J(=!W!OOEK$379D"MY%[\O_?CHN)406Z4;(D2GFEG<8_-8%81E,(H&!
M39Z.R);@/DC!<AH%M()Y8V";8Y S13,&;DTPV,IX. F4]-'X8?.CWLG)T4*#
MH@N4A>2#:X/+F_G:.HIT7%L/:2F _95Q6C.$3@5R8'/G2PZR2=:@4=A)QAB%
MBH8*Y0GUS E]?"TX5EIZ2!PMDC/I&0O1+GP2'<P+&U8 XDLP00L#(Z@CC!V&
M;\HM.B8&T'JJ'S:\46%.LHY>7< #K1/:3>%VA")9CVAA:)=Y/.9]7"X&\[H.
M?KPZ@?S)I  TJMZ0C&"^3=)6(H2+1.*6SI2V?&*.I/=7)A.R2RJ[/XTG-%8L
MB^1?&8F(&"./VJPC61F(JY5@3H1AP<?J7/K&0 .C#P10[1J]"=<(U(@6SLHM
M[08 H.0IT44PG/SG5'DC%?FTXBAB&8A83PA"T\EBA$: ]MKRTL5-99P=CE#A
M=>S:I;MU?66-HNN!5L00$=K)/!F:!<M?/O38(4^^R0CLXMS4MLKS^<6YGJ?(
M?.F8_81K@JDH2<Y\)XEB P D[H\TVP#ET"$80U4^!I+F/WW974![,0\GH=&$
MDM4'OSI0L2F'@FL0OI&4[&.&8;1A"O?F4,NWW\!#"6Z?*38&V$6BTO*FQL9(
MQSLY#6\M-T?H!S$MM1<HG4/^>BE\9UMJY57FAAV6=J2>5DL)[.<;4(_,ZG-M
M3;TV:^J$<@BF5T>0P0D#M)^GNDY2*D1AUWCS[-$\P2L2J<L6K;PSO6;IJBCG
M<.7Z3/ZN018$S :G<3\W)LRR=YV5_$;XBWN;H;683TAPD(@QJ\WN+446W)?=
M'F7<QBGMMZZUX^MG@0O:,!'DT%\&X-)"RS1".QOM"D*KZ 1[SNR- VGK8X$"
MA)X)IA3!&-!R)@SCMDT%@IL- K3(#ZP5THY50JG6><D:1'Y?3!3^R5)XBA[B
MF*OF"=3!'O@TJ7%I9 C@S*4\CE1SX)(:[6\ [567XG;8=PL3,X#?ODXTUY[&
M6T#7;#R1F*&5-(';[;@VFT/H@_@KDR#W*!H\C:O5]<+4J%/ JG0&N\O+D@0H
M%TS<DB40C[0"4!*KQP3RN\M9GJXSX_C4EJ'1&*@VM6PP4,[[&$,O;]B6I:73
MV?7'RG?C! ,S\J$@HPL=2YQ4?8EX:."FX#\!-RY'@>KRB%(5FG^5QX NGRFG
M ^/U,QA2B^%&=BO<C&J=.812,R#:S/X%,'&1H+9)Z&.58-.-&>5N2$;"[;G5
M5'F4Y<S+AG6A6-HC^:EDY?QB"R'5CNCKTAPV&V&)_K'RK4A*UR5A,<,V*63*
M[L%NR8,TFXQ<DO$=UT^Q@N"],BSR,:%$?'?'7BPMMQ^D#[0:G/ON"'Q'2[-X
M:1/2[/*E719ML*]\$LBSA!?%;$SNBW.;,?<2?17:MRK!_RBJ,;H=F^Q(A%Q2
MN8_<)3>);HF:\  7Z\J>N:U@5LY,QXT**DL1BK[3=X;S^R)0X]K K,7$+[W>
M8;X.C-@Z_H6^],@HQ0HELZP/8/"JJ'BWVKD;N]VG[,M#BHO5QQ 7;X.]5E9?
MS$H1=O4',]@7%34?BLGNB.V5Y96GU\<K:W<KLWH5@S6 ?D[S.G?)9Q%0'!UE
M<)!2Y7UK&A<,714@M?%J'-EGN,\KSW=#0\V^C\^^)U3<U>PO0)/I2JY%^\J@
M"^XT6Y<CDWL[80$MV0X%881J>L$PZ8M9- YM4:4Q3WQ3G?!=I[7"^GFY<O6G
M61>JFH5+96NS4MFD4A"D85:GBW%@ U%&^[\!]/GB,??/T&7'B$?DP@BFF YV
MV5FX=\^VPQES:.JK-%7A9@=1_*BS.,,51JOX(#>B%X]R [I4AJ44]KB'LWQA
MM!MN ?Q^K-]9>0S6K^;/=MJME8O,W[PF,VEJ-LP['H/YKXF9N(9OV]6+ J#L
M/^6(L3K$KH=2H!;U?.%];=Z50:92F"^0H#(;;<<YN!H6F>_EMT6(WR"?02 H
M@HHF\,%TU06\&GAN;+365M=7.N[?[C^W^E2:J4G;EV,M-MV'62?+6 C#+="9
MZ-]SW;G+ 6[S]$"NS$T!ROS672Y^NYY##)^Z[CH9%9\SK0+ILY_:],\%E0@T
M+1.Y_-V^H7R)3O;91$ZRK9B2@E-MV%_-[9?^3+,Z]6,5-=,',53ZOU[)REF_
M'=^8VZE0^FVX^RGH_"(H>6B3+.;?G1XO7"9&7@F$+Z7MC+)BJ_<G[;X,[ 9N
M3H?VX :)B.V=,EK93R:XY:*H)GW0>ZEX_M&0?=>ATGCX7PW81P)L1(E5@-A?
M.>C$&IDW1"8SI??86F.E!NAC #31*=71MUO"CCEYM.STN(;H#2':;=?"\X=B
MD[3[:8W/&I_/$Y^UAK^5[?GFX?E(E#4;&_*D@QJ0-P3D6O<Z6],% 1>KF6)/
MF?%6Q[3?:$R[6/J8"F(7R:KY!H<ZKOUCX]JKZY?'M9>Z=5S[*AOM(52@-.NC
M.YA>[_.$_8&I&%^Q(-,8CT3] GR!5AMM(GIW>NQR!5ZJKGQ&I#\$HYC"X/]<
MP!G(*5T;>0]*YG9>$WUEIKWRK$CZ7(BV7H/P0>GY\S E_.58[%QB/3\KVCX7
MZG4Z-1P?'HX$P1R0W1J0MP#D<@W(AP=D#<';0'#U(6(OZ+3.B'4\@H=>AV3J
MD$P>DB$_IXEE^/1(!7Z=;%@'92Y(QY<2E/EQR89/L#)2#0H5H2!*W)N5(?\B
M-/6SFN@Z%_*1C<IWS"Y5U<;E'9+*NF\^[?%QL;FV4F/SKMB\DG0U-N^-S4ZC
MEIQW2=:I8?FHL.S6L+S3_H4:EG42V3,BV[NEZVW+9YA%-EWNS'U\G+II/Z:^
M=UZRHZCF?2"XQC)VFY=&(7Y(1?K4' ^,]0H3$>#>?E.W;[I4(6[?+ZX.;1$X
M6QB0"A=@]5SIF]H%W/. '^@.V@^'WTTY>JR&"^^(,="!Y082.E_,U'LNBDJ=
M1E3-\#BEDB?S2+P%ZD)&90 ]8'20!U29@PA;]"RTA*5BA%A"05)]:S.LR^^W
MA3^@L9M7^["5MZ]XJ3E[V5"%F\.7L;XAA22HZO_%7MMRG880]-*^\'BF1;F0
M(WS59N:N:'H\$EA54>.I3$ Q.I4)PZYR,,'O*A:E8S)$Y!N"%:W\2\,](')-
M)<=KAPE]&F2!.08&JU&HQ$!&T9&=\&NB9Q61U#C!)BK=GUA:8?>&>)X5/$B'
M4<5X)J<W*2I*0'?PZ$XL_4C'0N6E+>RH$&4BH>(+98S:<ZUQ#G@TP7YD:68K
MFBGUK564UIDQ,8CP2.$Y5(P'T+7('#MCJE!.W0TLA;V>R0O80HOU\' LF([4
MO"<1GH)W!)*73Y*_@N9(:: :';R@TU(-5W;Y).7' LXHW?;<RF?>9"W%ZL[I
MI:@7M 01\F0H(],]GJ7*73"&!%VQJQ3KK:6UC=6N^W?I?JL4&]>O4G0O7Z7H
MW.VG*XHLW/&-]VZL//P2<:Y8Z[N_O6C/A+K2(+R7_3?#!D$)>$*5?40&(](-
M$/?>Y5S_^!TZFI)X)+A KN5B^# 7[/M8QNR/O(S9S")*>T8K_Z@AS;V?)P-*
M91JZH>^UNO 8D%+0U  D^^9(^B#L9DC)RT8[HP!7VRZ.8V3P6;I@3S[^7'8L
M728[GI 6,QZYQ@5=OK\+^EF-V1Z:@ -VQ*.AN -N:EP\)2ZFT_(? !4?H2O7
MP>)ZN1G"W 7BM="DT'.7%_:<J=W>"A,]1Q#<-T#W(D9*3]UWJ*N=NRXFO%KH
MOO;QU:SY0EAS^:VRYENS,3X+K3=+H=*;A[G?(#BJZ;S/#1\/P_DK;Y3QW\#X
M:NR^TKE]6TIK5A2[HK^N/0;C#4+D.F14PTQ+\3GS589+6P\;9[K%+H#'-NAG
MP.@N%OY+(]P#2-H9E%M9OJOL?7[T>Q9L68N=9\D]M=AY7F)GK18[=S88GV>>
MYQMI?@:8>WV5I>R6"1D_[$!KSK0G1>2)II_(,Q$UV#!0?1ZPOE3QB"<A]ZC#
M>"JSR:1C ^5EMM ?II7Y4GL(\DF#^>),!"JFM$4Z;SPO5BN_YWD?YH HR@/U
MY6 @\#QM22>OA<*7GHPHW9&G+I>2]44D!M+L9(_A-90_2+EU":;I0?O$C;IE
M\PUY7P8RG>#M9BS04KDGPAW!JI$ E/^JLL@W':26B12Z=-(6)?:Q1/4S#?V2
ML<#YH;0]S%BTYSZ=B=((*!LR2U@H-9UXC7VWX\'L5ZW-X7P:D].:7L#Q F9!
MFNQ(S#,LACI2;,3/\!@PED6A2$TS,".1$/[%P[7>-*_M ]T.%(#B4W$8U]/E
M7,_HX">7+ON4F>"]0)RS_^'1Y<E3C]^'_^JP^8WV^@+;Z'2;&ZO+2T_8%_X-
M:/'?<>J!S&N!I*@9*L?K 4@:_I18_16FAGW@?[ZZC2,76:"SNO:$9/ZSS_^L
M.>"IFY^MT?"(3_99J6_@@Y@],F0DW) KL;[-@U/I9&HC$9U$SV5$M@OVN!G8
M'I<V?:#19C<CA(+3T?1@0^&9J8=@<<%M[%AX&?@\6%_Z,_P9&J/L2* V9STO
MQ?L[&QLK+=8+*OM);/-NMX,L[7 RFU+ L(O*#\"+W,82AN>>-FC/Q^6=+Q^<
MFM(IK[F%4>SZ 3-2F).81X+3K51AJKU%><R_V&U4<^5W&4-6Z%AXM$MH7BZ8
MK&<LHFT-U?P0UWPC%IJ7\]+=2I%QO'2C,'G^EH8Y6+:@22*&,'CHU:8]33HU
M>Z6P;S12H$(<@,7K-N)0KXVY"K;W5N76J9$9Z[QRZ"R\+$4RE@F"+D:L4O(*
M<$/:,(.;5#)A.NM;:]JT7SFQEGD\-H8_8&?+'DQK-E#E&Y'^5!*^TK8)<.#S
MJ:,B6H":XX/>;?O1F.7B). H8)%T.A\N=&> Y@6YMFQOKJ05DC^0'DR7Q--X
MKZ!"T<69WM:)&(*O)NG6KWP2R+.$TSS!+#J';.9SZ-@$/(DX/;H7#@+^W7P&
MQN+F9.%9G7+#T^ :I6((7J';=^7VH.G\4K%M*59:IK3[S/YD$8^ RQ>!/*61
M?&YGE^KC=?+4H,/%7K86^XTX_@I!%/()GHQNM\A)>'=_0N\<*SQ.>6Y8<.H<
M KXQQ^:*4]GQ6Q]<0.@B?G1'A]-GFE3\!% 3D8^?H#'\D_)D*.BG?,KPRU@&
MYJ_* KK=<Q_TJ+B$FRDS;($X5@*J>(*SB"(827I3+_!1M,'-=>:C-&^]?A $
MQ0;61G5+8 (_CW"^G+( PMKH \.IPQ<'$U,C+QTI+1QM,<R1,!G&@07)%:"2
MX)CS;^C[8UC%=,0<'GG&$RE0'@Q8(O4WP[A99/>UHL2J:A?L@..R5!EAK+(4
M&%68X[<QR#!$X6,.";=L*<-^EF@C]"(Q5*DL2Q=0BHE/>V0G*(MPRZ:5VU2U
M=FU+%W$1##]8U>/!NX$94A>5P;A1)9I"=R-#56,L5L\;=KY>,^1]>#C]4-S$
M8]30/  R7ZXT<KE2/%?()T  /$2WY.$HF G\0U:&C_&R0 VEI]&:, &HZ1>6
M4(B/E^)E%1E/3$[%X7+UH6U C795X^-%?4<W*U:HJ7Z =A-!AP"Y19T040**
MSS0%K\&Y;5C<F"W?T!^= HFAJ<*,P3J3586)CZ!LAB=\>U8\LE<%\F;[M7L;
M=="R'(":U.+3NG./(H9B4EDI(#XA]5,.AA8$M?;&/0$]K;(M2Z']1J%%D#.^
M!/8)MZ:CHF9;.EC;G/D3T-,J1JL<IVL"<@.#DSRA&^WI]C2US:(W#ODE&P$/
M&T5I0ON,71P3[P.+5)/1&6:&^]ENYHU$%.$539OU\TY,V'P4[A[L+C@+:'^W
M9S Z-00KW8EV19=QG<;N<G=19NB-),:G#$AWT4+3O'SG8,=NG;>> < 97C'!
M??> 7 T0 1L!Y&!*%L@,@F*U$JI0(,FV2+X)VI7.,Q#ER6RC:C:Q</3YD8,9
MT$3@@</ KBH$-Z4'][+YO;W>0L6!& GKX)2>.<@#T;TA[::?WSOH+0 F@7-"
MN@ZM6%.+1Y'1G)$8(^4F7N"X%M]IY5T3-1?K\\!MLB];B)6!6M3H_(TH66#2
MJ[?-(*,146@"@N%40BF*41F*P')$;B##D.AO28(=$XC;RYT&@A:>!,)]%_"V
MSGHS!(X=D0/CB;YJHBS%]M"PK(#EYC,U@,?5V!@&0'37!IJZ41-DI@A [Z6"
M+.T&3)0$(I@U%]!\B"DGK.T*@;/S_$M!Y+"QU[M&I=K2!S=S""H8[V/1#?3L
M!9A'WK3C:R^3$  U JP[:=C^-IBP6 4R*U2K2%1TB JAAKJ'F!0L>6^$6\((
MBRD_+U60"/A8YQK1N P)F2!&#()G1%X>=0<(*'&%UZZ7T"E4%U:?2I*S,K<-
MY]<T$(S-7F]WI^$(U,BITRB$J9$-D\*E--V=MI5R+P@7UU*::C)".+(!],W6
M0JDH"5(-0/BMBCU4X@],U-:#"4F9 CAE=8W<K5TY"1.7X?!.8W @D*\T6&:P
MY"V;!%$OH16-41PT0. W%BA@C=PF(IP>2'^'QT5]'#.3.AL,)"U&E@B,2>N(
M:Y4EGIU_[$NIBZI/HI?[XJ\,0TC6: .T5DS0?/CP5V@AJ,"#L</+5XJ:(C9:
M8@TO'DNL3$47 ;]8]J/P1-&@1'L:ET(S<AILTW-'*#3WS<]S2!?'AF9T(>@3
M+ :"T_-[!J:Y2$#*'5%5&%Q?W4<=UVDW?Z>F>D903__\/PTTP,8B",@0 X!F
ML37921*@.X$=<?T<2)1ZQML!P4IWX5_H=1G6 SI.7!=GW!_O[;38'RJC4%D&
M[BS9F!Y\&V1FE15$'0*#8W .1;YM\4G=TUGI$C^T SU+0C+TJFOJAH\J?@"2
M7A"%RU+9^(T65I?Z#=;/N7SQ'11R[N6U*"%!V%HW; CX@Y:$T_W46RO8,$A!
M.,5%;G+WK,$SJW%D1G@6L)Q(_*5AW<DS8=:\2STCE4[+X0"@LJ*YK8PF)>.D
M]'1:Q<OW+IXXQG(RNBHV7HJ^(Z((%Q@^0;%F!,J9%&,0*Q$6_\JU!8HH\WEJ
M-<$:_<Q75*/+>E I>+,$)C!"$4M&RAD#XTS28Q,K=R[O*SI'8A"@G52-&>%[
M2A8)!;H;190;9:S.PMC:(R[JYX(E?QK9K@GM1GYZ,O&R$)J.4'4I#Y0B11T(
M8==10)QCC32D5H+5GA)C98)A=,.DH1^'PMG,]3>7@-97_N3]W[<71VD8O/]_
M4$L#!!0    ( (!"+5"'3[<QN ,  .<2   1    <'1C="TR,#(P,#$Q,RYX
M<V3-6-N.VR 0?=^OH'XGCC?J)=$F5;N]*-)V6^U%V[>*X$F"U@87<"Y_7\!V
M[%PVC>VHZH,E/,PYG('Q +YZOXHCM "IF.!#+^AT/02<BI#QV=![O,<?[J_'
M8^_]Z.+J%<8_/][=H$^"IC%PC:XE$ TA6C(]1T\AJ&<TE2)&3T(^LP7!. ,A
MUUBI<*#H'&*"B-:235(-7X2,/\&4I)$>>BG_G9*(31F$1D($=H@MATJW)G(&
M^I;$H!)"8>C-M4X&OK]<+CN)IA,F.E3$_F7WLML-@IZ'3)!<#2+&G[=\5Q,9
M=82<&<]NS[?=$Z*@<#=,^E1JR\2.<#.N-.%TP[W:T[+L.>^@W^_[KG?CJL)#
MCG9\_^>WFWLWJ=[H B$WR2Q.A-2([TW.E*B)0RJIL5XGH Q'T,?= /<"#V6+
M<R,HT2X5<I0+HPIU(!\BK4HB7!)UC 8/^?7DG$-(&PFIPC-"DOHRJL!,2FYI
M*T>*J,GZ'-3CN-H*:I@P!P4USIECW]4+<O8A]@T7.&Q-.+ALIZ*L'/54%+AS
MJ.C[1%*[U&;9J,:P2B+"B19R_<6\GZ8LDG*+Y7-)8B7VK<3@30N)CIG#S.X;
MITNJHLZJH\:T%(C6XX=:^O8#\+G@F)N=5#)ZFHPJ\C8#GE%-,R7-9507Y+5[
M"T]<C@K #ORZWI *:&<F%CX5*==R;2O3VV,E31T#%B^X9&FH)I72G+O6?ZVP
M^W*JR,U;D^JZ11L"JZ^E -E&:P6PHO/Z$C8HUVHM@O$%*'?4Z)VR[QV Y6U<
M4C13P@FCZJ_9^C(J:[9.5,6HI0OJB"@PMH%+<$,!.I&6[5VMM-B@7 N7^%T1
MA'.A'9,U%<8D87PJ,HNQV7U[4&S>=S!%[L ^R+?.X\=Z/Y$B :F9.4Y5;AR.
M8"YA.O3LO0,7%XQ?E$0=<Q$H7/8&V#Y6N&W*0&@:N2!N2I$%@RW<0T^9V8X@
MC_R?!Q7"M&Y0!L(X^X]CBLBD;DP& M%_&DXBH6XX!J+,K;U1XEF"!^. F+GM
M7HL%R!]D!L6_!@_9_L>[\4OW<3?^/JP8HQBE3*)1UX1I'H3+'QH8.09D*3;6
M*W\7N<.9*@B_\Y%K[\Y #LY=C@!W/MF3<=M?Q4%8;BPF."]K_DY=RPU;U<_5
MOOQ7#"(3I26Q?T2T3,WZV76R&?/+S5EBINQ#[N&Y$IZOXDX'BTS.VTS*2%1J
MNIA.[8A?I4B3H>?^I R8AMA#6<9D%D/!^&QL[#8*DU/.:C*:B?#!^86I=-)=
M;F7Q9'O#Z.(/4$L#!!0    ( (!"+5 0\,XW.@$  ( "   5    <'1C="TR
M,#(P,#$Q,U]C86PN>&ULG9)-;P(A$(;O_@I*SRRN>]*XFM9>3+9)HS%Z179T
MB2QL -WMOR]@M3'6I.F%KWEF7EZ&\;2K)3J!L4*K'*=)'R-07)="[7.\6I*7
MY6P^Q]-);_Q$R.9U4: WS8\U*(=F!IB#$K7"56A=@CV@G=$U6FMS$"=&R#D)
MQ844ZC *PY990)T5(\LKJ%FA.7-1NW*N&5':MFW2;8U,M-G30;^?T6O60R+L
MR 4CX8BD Y*E26=+C+Q#9:/V'T0N>'?'MUFDT^%P2&/TBEKQ&^C+IG3S7BRC
M3R*4=4QQP),>0N?G,%K" G8HS*O%_*9(X_A6Z(3KFH8PG6G?I ^VA\OS>_58
MI#*PR[''G3<>--,LV'Y^F. ^&\BQ%74CO5OZ<QW.)#_*V(W"[[_QH/Z_FYV%
MH'.@2BBCU)C>_(-)[PM02P,$%     @ @$(M4%(QFH>> 0  T@4  !4   !P
M=&-T+3(P,C P,3$S7V1E9BYX;6RUE%UOPB 4AN_]%:R[IEC-+C3JLKD;$Y<L
MFF6[I7"TQ (&T';_?H ?F]FZ+,[=M%#>\Y[GG *#VUJ6: O&"JV&29:V$P2*
M:2[4<I@\S_'=?#R9)+>CUN *X]?[V10]:+:1H!P:&Z ..*J$*] +![M""Z,E
M>M%F);84XUT0BH-2J%4_/')J =56]"TK0-*I9M3%W(5SZSXA556E=6[*5)LE
MZ;3;77*,:E2$&3[(</B$LP[N9FEM>8)\A<K&W+](<I#77_15-ZJS7J]'XNI1
M:L5W0F^;D=?'Z3S6B86RCBH&R:B%T*X=1I<P@P4*[^?9Y,1D[5@N=,JT)&&9
MC+7_24]T"8?V^^S1I#"P&"9>[GSA(6?6#65?-P:XMS4,$RODNO35D@\<:MB!
M:#_\#'5LEU".<"')7D-H69ZR-/3X)EKP@-F^B8B?(B\-Y<>@PI[&'!9T4[HS
M$1M]_A%82RK4WWE/;"Z.&]VQ!)F#.9?U.X]+@Q;>S[!-#OC8FC-Q?W!JA/:;
M1B@1[K>IG^[5@>N\L[[+ [4#Q8''3 -R<K..6N]02P,$%     @ @$(M4$8A
MNSFY"P  9&<  !4   !P=&-T+3(P,C P,3$S7VQA8BYX;6S-G6M/XT@6AK_W
MK_ R7W:E35/WRVBZ1W5=H66Z6TV/9K2K5102 ]&$&#FF@7^_92>A"4G Y0OP
MI3'!.?76FW.>NMA.__+K[>4L^9[FBVDV_W  WX.#))V/L\ET?O[AX/>3@3HQ
M1T<'OWY\]\O?!H,_]=?CQ&;CZ\MT7B0F3T=%.DENIL5%\L<D7?R5G.799?)'
MEO\U_3X:#)9O2JJ#V73^U\_E/Z>C19K<+J8_+\87Z>7H.!N/BJKMBZ*X^OGP
M\.;FYOWM:3Y[G^7GAP@ ?'C_KKUGE+\-UJ<-RI<&$ TP?'^[F!PDH8?S1=5V
MC4;6I]]NG7^#J[.AE/*P^NO]J8OIKA-#6'CXYV_')U4_!]/YHAC-Q^G!QW=)
MLK0CSV;IU_0L*7_^_O5HKSIY6)YQ.$_/2[^_I/DTFYP4H[PX'IVFLR"CBG:1
MIV>[0\SR?"-"Z9 L'8*L=.BG9P(7=U?IAX/%]/)J%NPY;*&_@>!B6VQ?ZBH3
M/C41^92KCP-VK/=;*-VT6\7;(3O6O$PT-Y_TD;^/PW:LO5O)O69&5HQF'6?&
M5LB]FF?E6<?A:'5B&?T)_%:-KZ#Z('!Z6Z3S23JIH+D1.IE./AR$H^%5,2Z&
M)@M#V-7H/%6GBR(?A5>DETY!YYB0VBOE,#$:(J>YH QI9H95E&$Z'_Q^LFZS
M>NG)J!8 1+F14E!/$99"4\@5,(SZT)*U!S&]W?8Q3Q?9=3Y>#D)!3CD&+Q5^
M')=:DE),\M^UG/_]<OA#=_<.358#?34^OZ93&T)Z<BP;;Q1)V:M0!.48#G%5
M KO[^=B0;-S6D&6_9N6T*,M7);7QN:I\G&3Y),W#=&W]IE$^?L;(U1F'XRS,
M0:Z*P4;VE=.V;L1GG23%TH,@>5?_[_-ZDDZ'Z\GHM_".H2$AG)9$"P(H\@ZC
M$'^9T9H +H?%_<BV-YVW@C+FE(6&. TE-<PHJYC60'+@#8<Z*I&+/2/K$UE\
M/]LNQ=2K]WA?GF9AKY;$4;">&X]JN12P" JJUA?I^/UY]OTP="JH@+(\&)0'
M P!7*X:?'G=X1Y$W]N1UR[NY[*QE+L27]/UTSH:IQQ X@1&&FDAGH'<"*LS6
M.:P]9K&UO1D=88&U<0R%$3'4"BE#$LV4!I9CIM%+%?E251)D):6N^'J/-*U^
MX??G5T,"U+6J2QALF/ ,%9H9]G;PT%#_#DZT<:(.,-R\F!9W7]/S:3G-F!>?
M1I=AS*.2(82TDEP9ZZ&"8#V[U8Q(6)<7NX,[H($SVE@.*:%(<Z0EHEYRJA%R
M?>-BJ2GY(2HI5=6'13/#GF=%[U[%H2+2IBY L<N!/9QH9=;K8Z*=_*RCI(F%
MQ-%\G.5765ZM)$_"@C(UV?6\R.],-DF'GCO.C' Z8$@1)#G#8%4"BA-;>_U0
MIRT$C5$ V3 GIQ1K)[EQ3C H):,,>/\R"%&323AI\<^DTA<R)OF29]^GX=./
MI4E+9^O"Y>5,;<2:#7D/7%V)3$J5+P"@)UUZDD?=^/M6\-11;[9HU:5+]>'E
MI[/TT_7E:9H/'7>*68V9 9XR:#D"J*HG+2"&1L>1ZD%@)8BVDFLKH O@%8I#
M"#% E )AD.Q[9F.R>3&:SM-)4FH*Y726Y9>K8JI>6<J,A5.,<W5)U)-IC;!3
MQYKNZ/*CYT^BI(%!;X4;3:1O0:)Q_^L3X=OH]F@25EC3L^GR*OHZR3%$6"F#
M%8&." 7#I'XUW!H".8C#P]Y66&"<(UA1 "A74BNGG)<&&.TUD7WOC*YR/ZA+
M-N4UA$1C,^L2XR5\;(2/> N[@\D>4YXD2ULCWPIF6O=CBSG=.%,?0*OUP^K'
M<1BYX=!:QPW#7$/K)'94< O7<WWJ.8^#SZX6"-*04FU##S EBDCJ)/*"AJ4B
M=U[Q%UX[K0Z24ESR>1Z]=&ID8EWH].U?(^#$6]<=<'88\B1LVACX5D#3J@];
MD&GO2#1@3#C\G'_+;N9#*A$@PGE"E'(4,T'8>BLAX$SX1GAY$-\8CS7F5GIN
M*(%8&<["NH!I2!SAYH7V=N\KI%16[B"4VAJ")<:\2*STY%L[J-2RK'.@_+"B
M#DX:&/?&8-*D!_M0TMB-:)!4FS6?\_4NY]!"'$K!2^&%Y, X:L,L?U40@JEF
MDY7'C6BG ,1>:H(@M98JI<,BT#NB#9,8P!=&2NN]WJ9>1L*E3QO;$::^@YUC
MYI$I=5C3U,<W!IS&W=A'G7:^1*/G2[8H1K/_3*^J36*LA'"(*Z(E4MAI"<E]
ML4 "52/P;#;A("#( V\ETY1[)@$//SP4UB,JM7MA["S%)4'=TY=!.G4Q$CG]
M&=@..'6]ZQPW&X;4@4TS!]\8:AIV8A]HVGA2!S/E]$GEZ:@*#Y4S4(35%^0(
M4.@HXF9=$AQ#4Q<LFT%9*#1/J%2(4.V,%)I3Q[QSB""+>K\L5!5#$!-)CCAC
MGF=%;Y[$T:&F'5W X&&/]Y1_(U->O^";R<Y:)D/]HBX?C)Q]N<CFZXM(5&$-
M/: LS%.,50I[@U?Y:TGX0]W"W@J,!:#$>^NY-=2'&K&0>2.0% )HBVG/Q5WI
M22I!T5=NXDUZOLA[]2>NT".LZ:+8'_=\3\$W-NCUB[ZY]*R#!*E?_'_DTZ)(
MYR:[O+R>KR[E+(;6.(2-%M:%#T_3,/55]\FMC:U]#_SNZ,A[X)3$BD(<%NQ
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M/[661.GX.JR^[B Z_38M9ND0 ,@Y5T(QY1G%PJ+[>Q.DH:CVX\!;@9U @CI
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M]V_^!U!+ 0(4 Q0    ( (!"+5!:)%D)7QX   2X   ,              "
M 0    !A.&LQ,3,R,"YH=&U02P$"% ,4    " " 0BU0MCF@NH<@  !(\@
M&@              @ &)'@  97AH:6)I=#DY,7!R97-S<F5L96%S92YH=&U0
M2P$"% ,4    " " 0BU0AT^W,;@#  #G$@  $0              @ %(/P
M<'1C="TR,#(P,#$Q,RYX<V102P$"% ,4    " " 0BU0$/#.-SH!  "  @
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E,#(P,#$Q,U]P<F4N>&UL4$L%!@     '  < S0$  "-9      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
